Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
January 02, 2019 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference
November 20, 2018 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology
September 26, 2018 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 30, 2018 16:07 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
July 20, 2018 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 20, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Pricing of Initial Public Offering
July 17, 2018 18:55 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 17, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and Acromegaly
June 21, 2018 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 21, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel...
Crinetics Pharmaceuticals Appoints Alan Krasner, M.D., as Chief Medical Officer
June 18, 2018 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 18, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel...
Crinetics Pharmaceuticals Completes $63.5 Million Series B Financing
March 13, 2018 14:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced it...
Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO 2018
March 12, 2018 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 12, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced an...